AM-101 in the Treatment of Acute Tinnitus (TACTT2)

To confirm the efficacy and safety of AM-101 in the treatment of peripheral tinnitus.

  1. Tinnitus Talk
    This phase III study is being conducted to confirm the efficacy and safety of AM-101 in the treatment of peripheral tinnitus in the acute stage (up to 3 months from onset).

    TACTT2 (US, CA, CZ, KR, TR, IL):
    Tinnitus onset no longer than 3 months prior to randomization
    Estimated Enrollment: 330
    Study Start Date: February 2014
    Estimated Study Completion Date: March 2016
    Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
If you have ringing ears then you've come to the right place. We are a friendly tinnitus support board, dedicated to helping you discuss and understand what tinnitus treatments may work for you.